RSS

Lonza

Lonza has expanded its footprint for parenteral dosage form development by investing in its Drug Product Services (DPS) site, the company has announced. Read more

News

Sven Stegemann, director of pharmaceutical business development, Lonza Pharma & Biotech, discusses how using sprinkle formulation technology helps manufacturers focus on the patient in medicine development. Read more

Opinion

Biotechnology company Lonza has announced an initiative with GE Healthcare in which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou, China (CN). Read more

News

Swiss multinational, Lonza Pharma & Biotech has opened its Collaborative Innovation Centre (CIC) in Israel to help accelerate new therapies and manufacturing practices. Read more

News

Capsule Delivery Solutions has launched a new capsule based on an “allcolorants” formulation, helping Lonza Capsugel expand its R&D offering. Read more

News

Alyn McNaughton, technical director for Lonza Edinburgh, Lonza Pharma & Biotech discusses the requirements and regulations surrounding serialisation legislation. Read more

Opinion

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Integrated solutions provider — Lonza — has announced the launch of a new bioscience website, designed to support the work of scientists across the bioresearch, drug discovery and pharmaceutical manufacturing fields. Read more

Technology

A Master Service Agreement has been entered by TxCell and Lonza Pharma & Biotech for the manufacture of a CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. Read more

News

A long-term contract extension has been agreed by Proteon Therapeutics and Lonza Pharma & Biotech for the commercial supply of the investigational vonapanitase’s active pharmaceutical ingredient (API). Read more

News

Lonza Pharma & Biotech has invested in a new phase of development at its Portsmouth, New Hampshire, USA site, which will include mid-scale mammalian capacity and the addition of new cell-therapy suites. Read more

News

Integrated solutions provider, Lonza, has opened a dedicated cell-and-gene-therapy facility with the capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Lonza and BioWa have entered into a licensing agreement with Tillotts Pharma for the POTELLIGENT CHOK1SV Cell Line Technology to be used in research and development of the proprietary antibody TP10. Read more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Supplier to the pharma, biotech and specialty ingredients markets, Lonza, has expanded its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in the US. Read more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Integrated solutions provider, Lonza, has announced it will be establishing centres of excellence for cell and gene therapy to support and accelerate its growth in this area. Read more

News

With festivities and holidays galore during the latter part of December we thought it would be a good idea to briefly run through some of the pharma news that came out in the run up to Christmas. Read more

News

Lonza and Massachusetts Eye and Ear (MEE) have granted Akouos (a new biotechnology company) licences for exclusive rights to the ancestral adeno-associated viral vectors (Anc-AAV) gene therapy platform for all hearing and balance disorders. Read more

News